关于减少公司注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于 2025 年 10 月 29 日召开第十一届董事会第二十二次会议，审议通过了《关于回购注销 部分限制性股票的议案》、《关于减少注册资本暨修订<公司章程>的议案》。公司 《2021 年限制性股票激励计划》（以下简称"《激励计划》"）授予的 6 名激励 对象发生工作调动、退休，不再具备激励资格。董事会同意公司在回购注销部分 限制性股票完成后，根据中国证券登记结算有限责任公司上海分公司确认的总股 本，变更注册资本、对《公司章程》相关条款做出修订并办理工商变更登记。根 据公司 2021 年 12 月 10 日召开的 2021 年第五次临时股东大会授权，本议案无需 提交股东会审议。 本次回购注销完成后，公司总股本由 606,677,919 股减少至 606,644,549 股，注册资本由人民币 606,677,919 元减少至 606,644,549 元（具体以实际核准 的 ...

Core Insights - The company reported a revenue of 2.188 billion yuan for the third quarter, representing a year-on-year decline of 2.20% [1] - The net profit for the third quarter was 48.5929 million yuan, showing a significant year-on-year decrease of 63.39% [1] - For the first three quarters, the total revenue amounted to 6.978 billion yuan, which is a year-on-year decline of 6.00% [1] - The net profit for the first three quarters was 434 million yuan, reflecting a year-on-year decrease of 29.61% [1]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-052 山东新华医疗器械股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 28 日 (二) 股东大会召开的地点：淄博市高新技术产业开发区泰美路 7 号新华医疗 科技园办公楼三楼会议室 本次股东大会由公司董事会召集，董事长王玉全先生主持，会议采用现场投 票与网络投票相结合的方式表决，符合《公司法》、《公司章程》等法律、法规 及规范性文件的规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 1、议案名称：关于取消监事会、修订《公司章程》的议案 审议结果：通过 表决情况： (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 351 | | --- | --- | | 2、出席会议的股东所持有表决权的股 ...

2025 年第一次临时股东大会的法律意见书 致：山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）受山东新华医疗器械股份有限公 司（以下简称"公司"）的委托，指派律师出席 2025 年 10 月 28 日上午 9:00 点召 开的公司 2025 年第一次临时股东大会（以下简称"本次股东大会"）；依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等 现行法律、法规和其他规范性文件及《山东新华医疗器械股份有限公司章程》的 规定，特就公司本次股东大会相关事宜，出具本法律意见书。 对本法律意见书的出具，本所特作如下声明： 北 京 市 东 城 区 北 三 环 东 路 36 号环球 贸易中心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 1、本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前 已经发生或者存 ...

Market Overview - On October 21, the Shanghai Composite Index rose by 1.36%, the CSI 300 increased by 1.53%, the STAR 50 climbed by 2.81%, the CSI 1000 went up by 1.45%, the ChiNext Index surged by 3.02%, and the Hang Seng Index gained 0.65% [6] - The best-performing sectors on October 21 were telecommunications (+4.9%), electronics (+3.5%), construction decoration (+2.36%), comprehensive (+2.29%), and real estate (+2.25%). The worst-performing sectors included coal (-1.02%), food and beverage (+0.23%), transportation (+0.29%), beauty and personal care (+0.31%), and banking (+0.33%) [6] - The total trading volume for the A-share market on October 21 was 1,892.693 billion yuan, with a net inflow of 1.171 billion Hong Kong dollars from southbound funds [6] Key Recommendations - The report highlights Zhongrun Optical (688307) as a leading domestic brand in high-magnification optical zoom lenses, expanding into new fields such as drones and mobile robots. The company is expected to double its performance due to industry growth and increased market share from domestic replacements [7][8] - The report argues against the prevailing market view that new downstream products will only provide temporary boosts to the optical lens industry, asserting that the long-term outlook remains positive due to factors such as import substitution and the company's unique technological capabilities [7] - The target price for Zhongrun Optical is set at 66.27 yuan, with projected revenues of 660 million yuan, 1,170 million yuan, and 1,645 million yuan for 2025-2027, reflecting growth rates of 45%, 77%, and 44% respectively [8] Important Insights - The macroeconomic report anticipates a slight decline in economic growth to 4.7% in the fourth quarter, with an overall growth target of around 5% for the year, despite challenges [10] - The report emphasizes that there may be additional stimulus policies in the fourth quarter, with significant measures potentially being reserved for the first quarter of the following year to ensure a strong start [10] Industry Analysis - The medical device industry is expected to see accelerated innovation and international expansion, particularly in areas such as cardiac intervention, biological materials, and surgical robots. Companies like United Imaging Healthcare and Mindray Medical are highlighted as key players [11] - The report identifies catalysts for growth in the medical device sector, including moderate price reductions, the recovery of tenders, and the acceleration of new product launches [11]

Core Viewpoint - Xinhua Medical (600587) has shown a slight increase in stock price, but the company is facing declining revenues and profits, indicating potential challenges ahead in the medical device industry [1][3]. Financial Performance - As of October 20, 2025, Xinhua Medical's stock closed at 16.44 yuan, up 1.48% with a trading volume of 79,700 hands and a turnover of 131 million yuan [1]. - The company reported a total revenue of 4.79 billion yuan for the first half of 2025, a year-on-year decrease of 7.64%, and a net profit of 386 million yuan, down 20.35% year-on-year [3]. - The second quarter of 2025 saw a single-quarter revenue of 2.48 billion yuan, a decline of 6.59% year-on-year, and a net profit of 225 million yuan, down 17.55% year-on-year [3]. Market Position - Xinhua Medical's total market capitalization is 9.974 billion yuan, with a net asset value of 8.188 billion yuan, ranking 38th in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) is 12.93, significantly lower than the industry average of 65.67, indicating a potentially undervalued stock [3]. - The gross margin stands at 25.21%, which is considerably lower than the industry average of 51.83%, suggesting operational inefficiencies [3]. Investment Sentiment - In the last 90 days, two institutions have rated Xinhua Medical with a "buy" recommendation, and the average target price set by these institutions is 20.0 yuan [4].

Group 1 - The core point of the article is that Xinhua Medical announced its profit distribution plan for the first half of 2025, which includes a cash dividend of 0.25 yuan per share (tax included) for A-shares [1] - The record date for the dividend is set for October 23, 2025, and the ex-dividend date is October 24, 2025 [1]

Group 1: Jinshi Yao - Jinshi Yao expects net profit for the first three quarters of 2025 to be between 86.61 million and 107 million yuan, representing a year-on-year increase of 48.99% to 83.95% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 69.13 million and 89.45 million yuan, with a year-on-year growth of 32.83% to 71.88% [1] - The company specializes in the research, production, and sales of pharmaceuticals and health foods [1] Group 2: High Energy Environment - High Energy Environment, as a member of a consortium, won a bid for a wastewater treatment facility renovation project valued at 53.64 million yuan [1] - The project has a duration of 9 months [1] - The company focuses on solid waste and hazardous waste resource utilization, environmental operation services, and environmental engineering [2] Group 3: Shentong Technology - Shentong Technology reported a net profit of 113 million yuan for the first three quarters of 2025, a year-on-year increase of 584.07% [3] - The company achieved a revenue of 1.302 billion yuan, reflecting a growth of 34.65% [3] - Shentong Technology specializes in the research and manufacturing of automotive power systems and optical components [3] Group 4: Pianzaihuang - Pianzaihuang reported a net profit of 2.129 billion yuan for the first three quarters of 2025, a year-on-year decrease of 20.74% [4] - The company's revenue for the same period was 7.442 billion yuan, down 11.93% year-on-year [4] - Pianzaihuang operates in the pharmaceutical manufacturing and cosmetics industries [4] Group 5: Yingxi Network - Yingxi Network's net profit for the first three quarters of 2025 was 422 million yuan, up 12.68% year-on-year [5] - The company reported a revenue of 4.293 billion yuan, reflecting an 8.33% increase [5] - Yingxi Network focuses on AI interaction and smart living solutions [5] Group 6: Tengjing Technology - Tengjing Technology achieved a net profit of 63.80 million yuan for the first three quarters of 2025, a year-on-year increase of 15% [6] - The company's revenue was 425 million yuan, up 28.11% year-on-year [6] - Tengjing Technology specializes in precision optical components and optical testing instruments [6] Group 7: Huayuan Biological - Huayuan Biological reported a net profit of 234 million yuan for the first three quarters of 2025, a decrease of 3.07% year-on-year [7] - The company's revenue was 936 million yuan, down 0.20% year-on-year [7] - Huayuan Biological operates in the vitamin and pharmaceutical manufacturing sectors [7] Group 8: Yipin Hong - Yipin Hong's subsidiary received a drug registration certificate for Methanesulfonate Injection, indicating it has passed consistency evaluation [8] - The drug is primarily used for counteracting residual muscle relaxation after surgery and treating myasthenia gravis [8] - Yipin Hong focuses on the research, production, and sales of pharmaceuticals [8] Group 9: Xinjiang Jiaojian - Xinjiang Jiaojian won a bid for a highway construction project valued at 556 million yuan [9] - The company specializes in civil engineering and infrastructure construction [9] Group 10: Shenneng Shares - Shenneng Shares reported a 2.6% decrease in electricity generation for the first three quarters of 2025, totaling 43.374 billion kWh [10] - The average on-grid electricity price was 0.497 yuan per kWh [10] - The company focuses on electricity and natural gas development and management [10] Group 11: Xinhua Medical - Xinhua Medical received registration certificates for two new Class II medical devices [11] - The products include a dental implant mobile device and a mobile laser simulation positioning system [11] - Xinhua Medical specializes in the manufacturing and sales of medical devices and pharmaceutical equipment [11] Group 12: Jingneng Power - Jingneng Power reported a 2.91% decrease in on-grid electricity for the first three quarters of 2025, totaling 66.469 billion kWh [12] - The company focuses on electricity and heat production and sales [12] Group 13: Tunnel Shares - Tunnel Shares reported a total bid amount of 69.029 billion yuan for the first three quarters of 2025, a year-on-year increase of 5.06% [13] - The company specializes in urban infrastructure design and construction [13] Group 14: Yongmaotai - Yongmaotai signed a strategic cooperation framework agreement with a leading humanoid robot company [14] - The collaboration will focus on the development of new materials and the establishment of a super supply chain platform [14] - Yongmaotai specializes in the research and production of aluminum alloys and automotive components [14] Group 15: China Nuclear Construction - China Nuclear Construction reported new contracts totaling 1129.62 billion yuan and revenue of 731.80 billion yuan [15] - The company focuses on nuclear power engineering and industrial construction [15] Group 16: Changchun High-tech - Changchun High-tech's subsidiary received FDA acceptance for a clinical trial application for a targeted drug for advanced solid tumors [17] - The drug has also been accepted for clinical trials in China [17] - The company specializes in biopharmaceuticals and traditional Chinese medicine [17] Group 17: Baiyun Mountain - Baiyun Mountain's subsidiary has initiated a Phase III clinical trial for a throat medication [18] - The product is exclusively owned by Wanglaoji [18] - Baiyun Mountain operates in the pharmaceutical and health product sectors [18] Group 18: Jincheng Pharmaceutical - Jincheng Pharmaceutical's subsidiary received approval for a supplemental application for a drug used to treat menopausal symptoms [19] - The approval allows changes in excipients and production processes [19] - Jincheng Pharmaceutical specializes in the research and production of pharmaceuticals [19] Group 19: Zhonghong Medical - Zhonghong Medical's subsidiary obtained registration certificates for two types of disposable nutrition pump tubes [20] - The products are designed for delivering nutritional fluids [20] - Zhonghong Medical focuses on health protection products and medical devices [20] Group 20: Bichuang Technology - Bichuang Technology's vice president resigned for personal reasons [21] - The company specializes in intelligent sensing and precision optical instruments [21] Group 21: Guangha Communication - Guangha Communication's application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [23] - The company provides communication network solutions for various industries [23] Group 22: Buchang Pharmaceutical - Buchang Pharmaceutical's subsidiary signed a contract for pharmacokinetics and toxicology testing worth 10.8 million yuan [24] - The company specializes in traditional Chinese medicine [24] Group 23: Jinchuan Group - Jinchuan Group's shareholder plans to reduce their stake by up to 3% [26] - The company specializes in rail transit vehicle components [26] Group 24: Shandong Road and Bridge - Shandong Road and Bridge's subsidiary plans to acquire a limited partnership interest for 140 million yuan [27] - The company specializes in road and bridge engineering [27] Group 25: TBEA - TBEA's subsidiary plans to acquire a 74.19% stake in Shuguang Cable for 946 million yuan [29] - The company specializes in power transmission and new energy [29] Group 26: Junshi Biological - Junshi Biological's clinical trial for a lung cancer treatment has been approved by the FDA [30] - The company specializes in innovative drug development [30] Group 27: YTO Express - YTO Express's shareholder plans to transfer up to 2% of the company's shares [31] - The company specializes in logistics and express delivery services [31] Group 28: Satellite Chemical - Satellite Chemical's subsidiary has completed maintenance and resumed normal production [32] - The company specializes in chemical production [32] Group 29: Longbai Group - Longbai Group's subsidiary plans to acquire titanium dioxide business assets for 69.9 million USD [33] - The company specializes in titanium dioxide and related products [33] Group 30: Jingda Shares - Jingda Shares' actual controller plans to reduce their stake by up to 3% [34] - The company specializes in special electromagnetic wires and precision molds [34] Group 31: Jinghe Integration - Jinghe Integration's subsidiary plans to implement a capital increase [35] - The company specializes in semiconductor manufacturing [35] Group 32: Zhaofeng Shares - Zhaofeng Shares signed a strategic cooperation agreement with a robotics company [36] - The company specializes in automotive components [36] Group 33: Jiulian Technology - Jiulian Technology announced a three-month delay in disclosing a major asset restructuring plan [37] - The company specializes in smart terminal and communication solutions [37] Group 34: Guosheng Technology - Guosheng Technology's investment target has not yet commenced actual operations [38] - The company specializes in photovoltaic battery production [38] Group 35: Kailong High-tech - Kailong High-tech plans to establish a joint venture with related parties [40] - The company specializes in air pollution control equipment [40] Group 36: Shijia Photon - Shijia Photon reported a net profit of 300 million yuan for the first three quarters of 2025, a year-on-year increase of 727.74% [42] - The company achieved a revenue of 1.56 billion yuan, reflecting a growth of 113.96% [42] - Shijia Photon specializes in optical integrated chips and related technology [42] Group 37: Furan Energy - Furan Energy reported a net profit of 490 million yuan for the first three quarters of 2025, a year-on-year increase of 6.07% [43] - The company achieved a revenue of 23.501 billion yuan, reflecting a growth of 5.38% [43] - Furan Energy specializes in urban gas and renewable energy [43] Group 38: Kanghua Biological - Kanghua Biological reported a net profit of 189 million yuan for the first three quarters of 2025, a year-on-year decrease of 53.41% [44] - The company achieved a revenue of 840 million yuan, down 20.78% year-on-year [44] - Kanghua Biological specializes in vaccine production and sales [44] Group 39: Cangge Mining - Cangge Mining reported a net profit of 2.751 billion yuan for the first three quarters of 2025, a year-on-year increase of 47.26% [45] - The company achieved a revenue of 2.401 billion yuan, reflecting a growth of 3.35% [45] - Cangge Mining specializes in the production and sales of potassium chloride and lithium carbonate [45] Group 40: Huadong CNC - Huadong CNC reported a net profit of 23.12 million yuan for the first three quarters of 2025, a year-on-year increase of 151.78% [47] - The company achieved a revenue of 249 million yuan, down 3.21% year-on-year [47] - Huadong CNC specializes in CNC machine tools and related components [47] Group 41: Yunnan Energy Investment - Yunnan Energy Investment plans to invest 1.872 billion yuan in a compressed air energy storage project [48] - The project will have a capacity of 350MW/1750MWh and is expected to take 18 months to complete [48] - Yunnan Energy Investment specializes in renewable energy and salt production [48] Group 42: Oriental Cable - Oriental Cable announced recent project wins totaling approximately 2.374 billion yuan [49] - The projects include various cable supply and installation works [49] - Oriental Cable specializes in power engineering and cable manufacturing [49]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-051 山东新华医疗器械股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.25元。 相关日期 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 3 日的2024年年度股东会审议通过。 2024 年年度股东大会审议通过了《2024 年度利润分配预案和提请股东大会授权董事会制 定 2025 年中期分红方案的议案》，股东大会授权董事会在符合利润分配条件下，制定并实施 具体的 2025 年中期利润分配方案。2025 年 10 月 10 日召开的公司第十一届董事会第二十一 次会议审议通过了《关于公司 2025 年中期利润分配方案的议案》。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 ...

Core Viewpoint - Xinhua Medical (600587.SH) has received the Medical Device Registration Certificate from the Shandong Provincial Drug Administration for two products, enhancing its offerings in the dental implant and radiation therapy sectors [1] Group 1: Product Development - The "Dental Implant Mobile Device" has been successfully registered, complementing the existing oral implant products and enriching the company's dental implant product line [1] - The approval of the "Mobile Laser Simulation Positioning System" enhances the competitiveness of the company's radiation therapy positioning products, meeting the demand for precise radiation therapy [1] Group 2: Market Impact - The new products provide a more comprehensive dental implant solution for clinical applications, promoting efficient development in the dental implant field [1] - The high precision and reliability of the mobile laser system improve treatment outcomes and enhance the company's brand recognition in the radiation therapy equipment sector [1]